Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer
J. D. Hampton, E. J. Peterson, S. J. Katner…·J. E. Koblinski
This study identifies sulfated glycosaminoglycan (sGAG) levels as a biomarker predicting response to Triplatin in triple-negative breast cancer (TNBC), showing improved efficacy compared to carboplatin in sGAG-high tumors.